Cardiff Oncology, INC Form 4 insider transactions

Director James O. Armitage acquired 29,700 stock options in Cardiff Oncology, Inc. on June 27, 2024.

Director Rodney S. Markin of Cardiff Oncology, Inc. reports the acquisition of 29,700 stock options on June 27, 2024.

James E. Levine, CFO of Cardiff Oncology, reports the acquisition of 205,008 stock options with an exercise price of $3.51, vesting over four years.

Fairooz Kabbinavar, Chief Medical Officer of Cardiff Oncology, received stock options for 205,008 shares on March 7, 2024.

Tod Smeal, Chief Scientific Officer of Cardiff Oncology, reports the acquisition of stock options.

Cardiff Oncology's CEO, Mark Erlander, reports the acquisition of 510,000 stock options.